47.34 USD
-0.37 (-0.78%)
47.34 USD
0 (0%)
Overall VCYT gets a fundamental rating of 6 out of 10. We evaluated VCYT against 533 industry peers in the Biotechnology industry. VCYT is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. VCYT has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
VCYT had positive earnings in the past year.
VCYT had a positive operating cash flow in the past year.
VCYT had negative earnings in 4 of the past 5 years.
In multiple years VCYT reported negative operating cash flow during the last 5 years.
1.2 Ratios
With an excellent Return On Assets value of 2.22%, VCYT belongs to the best of the industry, outperforming 89.87% of the companies in the same industry.
The Return On Equity of VCYT (2.41%) is better than 90.99% of its industry peers.
Looking at the Return On Invested Capital, with a value of 2.93%, VCYT belongs to the top of the industry, outperforming 90.24% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.22% | ||
| ROE | 2.41% | ||
| ROIC | 2.93% |
ROA(3y)-2.66%
ROA(5y)-4.4%
ROE(3y)-2.83%
ROE(5y)-4.73%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Profit Margin value of 6.12%, VCYT belongs to the best of the industry, outperforming 90.81% of the companies in the same industry.
VCYT's Operating Margin of 9.70% is amongst the best of the industry. VCYT outperforms 91.74% of its industry peers.
With an excellent Gross Margin value of 68.53%, VCYT belongs to the best of the industry, outperforming 80.68% of the companies in the same industry.
VCYT's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 9.7% | ||
| PM (TTM) | 6.12% | ||
| GM | 68.53% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.39%
GM growth 5Y-0.79%
2. Health
2.1 Basic Checks
VCYT has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for VCYT has been increased compared to 1 year ago.
The number of shares outstanding for VCYT has been increased compared to 5 years ago.
VCYT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
VCYT has an Altman-Z score of 20.83. This indicates that VCYT is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 20.83, VCYT belongs to the top of the industry, outperforming 90.24% of the companies in the same industry.
VCYT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 20.83 |
ROIC/WACC0.34
WACC8.64%
2.3 Liquidity
A Current Ratio of 6.23 indicates that VCYT has no problem at all paying its short term obligations.
With a decent Current ratio value of 6.23, VCYT is doing good in the industry, outperforming 65.67% of the companies in the same industry.
VCYT has a Quick Ratio of 5.94. This indicates that VCYT is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of VCYT (5.94) is better than 63.79% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.23 | ||
| Quick Ratio | 5.94 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 353.33% over the past year.
The Revenue has grown by 16.41% in the past year. This is quite good.
VCYT shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 29.93% yearly.
EPS 1Y (TTM)353.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%26.32%
Revenue 1Y (TTM)16.41%
Revenue growth 3Y26.64%
Revenue growth 5Y29.93%
Sales Q2Q%13.82%
3.2 Future
The Earnings Per Share is expected to grow by 50.66% on average over the next years. This is a very strong growth
Based on estimates for the next years, VCYT will show a quite strong growth in Revenue. The Revenue will grow by 9.91% on average per year.
EPS Next Y33.17%
EPS Next 2Y67.82%
EPS Next 3Y57.77%
EPS Next 5Y50.66%
Revenue Next Year12.89%
Revenue Next 2Y11.38%
Revenue Next 3Y10.9%
Revenue Next 5Y9.91%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 124.58, which means the current valuation is very expensive for VCYT.
Based on the Price/Earnings ratio, VCYT is valued cheaply inside the industry as 89.12% of the companies are valued more expensively.
When comparing the Price/Earnings ratio of VCYT to the average of the S&P500 Index (26.31), we can say VCYT is valued expensively.
VCYT is valuated quite expensively with a Price/Forward Earnings ratio of 56.03.
VCYT's Price/Forward Earnings ratio is rather cheap when compared to the industry. VCYT is cheaper than 89.31% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of VCYT to the average of the S&P500 Index (36.59), we can say VCYT is valued expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 124.58 | ||
| Fwd PE | 56.03 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of VCYT indicates a rather cheap valuation: VCYT is cheaper than 90.81% of the companies listed in the same industry.
92.50% of the companies in the same industry are more expensive than VCYT, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 37.92 | ||
| EV/EBITDA | 47.4 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates VCYT does not grow enough to justify the current Price/Earnings ratio.
The decent profitability rating of VCYT may justify a higher PE ratio.
VCYT's earnings are expected to grow with 57.77% in the coming years. This may justify a more expensive valuation.
PEG (NY)3.76
PEG (5Y)N/A
EPS Next 2Y67.82%
EPS Next 3Y57.77%
5. Dividend
5.1 Amount
VCYT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
47.34
-0.37 (-0.78%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners109.55%
Inst Owner Change3.31%
Ins Owners0.56%
Ins Owner Change-1.68%
Market Cap3.72B
Revenue(TTM)495.14M
Net Income(TTM)30.32M
Analysts83.33
Price Target48.22 (1.86%)
Short Float %7.72%
Short Ratio6.52
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-15.65%
Min EPS beat(2)-110.32%
Max EPS beat(2)79.03%
EPS beat(4)2
Avg EPS beat(4)-1.91%
Min EPS beat(4)-110.32%
Max EPS beat(4)79.03%
EPS beat(8)5
Avg EPS beat(8)108.97%
EPS beat(12)8
Avg EPS beat(12)67.3%
EPS beat(16)12
Avg EPS beat(16)58.01%
Revenue beat(2)2
Avg Revenue beat(2)4.54%
Min Revenue beat(2)3.31%
Max Revenue beat(2)5.76%
Revenue beat(4)3
Avg Revenue beat(4)2.42%
Min Revenue beat(4)-0.39%
Max Revenue beat(4)5.76%
Revenue beat(8)7
Avg Revenue beat(8)4.03%
Revenue beat(12)11
Avg Revenue beat(12)4.6%
Revenue beat(16)15
Avg Revenue beat(16)5.32%
PT rev (1m)14.68%
PT rev (3m)14.68%
EPS NQ rev (1m)10.34%
EPS NQ rev (3m)16.36%
EPS NY rev (1m)5.86%
EPS NY rev (3m)6.58%
Revenue NQ rev (1m)0.31%
Revenue NQ rev (3m)0.46%
Revenue NY rev (1m)0.04%
Revenue NY rev (3m)0.29%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 124.58 | ||
| Fwd PE | 56.03 | ||
| P/S | 7.52 | ||
| P/FCF | 37.92 | ||
| P/OCF | 34.4 | ||
| P/B | 2.96 | ||
| P/tB | 9.36 | ||
| EV/EBITDA | 47.4 |
EPS(TTM)0.38
EY0.8%
EPS(NY)0.84
Fwd EY1.78%
FCF(TTM)1.25
FCFY2.64%
OCF(TTM)1.38
OCFY2.91%
SpS6.29
BVpS15.99
TBVpS5.06
PEG (NY)3.76
PEG (5Y)N/A
Graham Number11.69
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.22% | ||
| ROE | 2.41% | ||
| ROCE | 3.71% | ||
| ROIC | 2.93% | ||
| ROICexc | 4.08% | ||
| ROICexgc | 54.52% | ||
| OM | 9.7% | ||
| PM (TTM) | 6.12% | ||
| GM | 68.53% | ||
| FCFM | 19.83% |
ROA(3y)-2.66%
ROA(5y)-4.4%
ROE(3y)-2.83%
ROE(5y)-4.73%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.39%
GM growth 5Y-0.79%
F-Score8
Asset Turnover0.36
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 44.87% | ||
| Cap/Sales | 2.03% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 153.79% | ||
| Profit Quality | 323.94% | ||
| Current Ratio | 6.23 | ||
| Quick Ratio | 5.94 | ||
| Altman-Z | 20.83 |
F-Score8
WACC8.64%
ROIC/WACC0.34
Cap/Depr(3y)39.24%
Cap/Depr(5y)36.19%
Cap/Sales(3y)2.72%
Cap/Sales(5y)2.61%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)353.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%26.32%
EPS Next Y33.17%
EPS Next 2Y67.82%
EPS Next 3Y57.77%
EPS Next 5Y50.66%
Revenue 1Y (TTM)16.41%
Revenue growth 3Y26.64%
Revenue growth 5Y29.93%
Sales Q2Q%13.82%
Revenue Next Year12.89%
Revenue Next 2Y11.38%
Revenue Next 3Y10.9%
Revenue Next 5Y9.91%
EBIT growth 1Y426.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year275.46%
EBIT Next 3Y68.01%
EBIT Next 5Y45.61%
FCF growth 1Y237.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y181.75%
OCF growth 3YN/A
OCF growth 5YN/A
VERACYTE INC / VCYT FAQ
What is the fundamental rating for VCYT stock?
ChartMill assigns a fundamental rating of 6 / 10 to VCYT.
What is the valuation status for VCYT stock?
ChartMill assigns a valuation rating of 5 / 10 to VERACYTE INC (VCYT). This can be considered as Fairly Valued.
How profitable is VERACYTE INC (VCYT) stock?
VERACYTE INC (VCYT) has a profitability rating of 6 / 10.
How financially healthy is VERACYTE INC?
The financial health rating of VERACYTE INC (VCYT) is 8 / 10.
What is the expected EPS growth for VERACYTE INC (VCYT) stock?
The Earnings per Share (EPS) of VERACYTE INC (VCYT) is expected to grow by 33.17% in the next year.